Evaluation of 3D Magnetic Resonance Spirometry: Comparison with Spirometry in Healthy Subjects and Patients with Respiratory Pathologies (asthma, COPD, Bilateral Lung Transplant)
Main objectiif / Evaluate the concordance of the results provided by 3D spirometry using compared with those obtained by spirometry in four populations: healthy four populations: healthy volunteers, asthma patients, patients with chronic obstructive pulmonary, chronic obstructive pulmonary disease (COPD) and lung transplant patients. with and without bronchiolitis obliterans syndrome (BOS). obliterative bronchiolitis syndrome (BOS).
Age
18–90
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Ability to understand the nature and objectives of the study
Ability to remain immobile in an MRI scanner in supine position for the entire duration of the acquisitions
Age: 18-45 years
No known and diagnosed pulmonary pathology such as respiratory insufficiency, COPD, asthma or cancer
Ability to remain motionless in an MRI scanner in a prone position for a total of 50 min.
Age: 18-80 years
Asthma of varying degrees of severity, depending on inhalation required to achieve control:
Diagnosis of asthma classified as moderate according to the Global initiative for asthma (GINA) guidelines for at least 6 months
Diagnosis of asthma classified as severe according to the Global initiative for asthma (GINA) guidelines for at least 6 months months with initiation of biotherapy planned by their pulmonologist
Age: 40-80 years
COPD of varying degrees of severity:
Diagnosis of COPD classified as moderate according to the Global initiative for chronic obstructive lung disease guidelines (GOLD 2: VEMS = 50-79%)
Age: 18-90 years
Irreversible FEV1 \< 80% of baseline with FEV1/FVC ratio FEV1/FVC \< 0.7
Absence of visible parenchymal opacity on CT scan (non inclusion of mixed RAS/CLAD)
Absence of significant bronchial stenosis (having required endoscopic endoscopic treatment)
Age: 18-90 years
FEV1 \> 90% baseline for more than 24 months after the date of date of lung transplantation
Absence of significant bronchial stenosis (requiring endoscopic endoscopic treatment)
Absence of diaphragmatic impairment (established by sniff test under fluoroscopy or diaphragmatic ultrasound)